Advertisement

Current Cardiology Reports

, 19:107 | Cite as

Evolving Indications for Transcatheter Aortic Valve Interventions

  • Anna Franzone
  • Thomas Pilgrim
  • Stefan Stortecky
  • Stephan WindeckerEmail author
Valvular Heart Disease (T Kiefer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Valvular Heart Disease

Abstract

Purpose of Review

The purpose of this review was to summarize recent progress in the field of transcatheter aortic valve replacement (TAVR), discuss expansion of indications, and identify areas of future clinical applications.

Recent Findings

Favorable clinical outcomes as well as continued refinement of transcatheter heart valve technology have prompted the continuous expansion of indications for TAVR. The results of randomized clinical trials comparing the safety and efficacy of TAVR relative to conventional surgical aortic valve replacement (SAVR) in lower- than high-risk patients have recently been published, and trials among lower-risk categories are ongoing. Furthermore, evidence of the feasibility and safety of TAVR in patients with other pathological conditions is accumulating.

Summary

Large pivotal randomized studies support the extension of TAVR to intermediate-risk patients. Moreover, TAVR is emerging as a valuable treatment option for other categories including patients with bicuspid aortic valve, those with pure native aortic regurgitation deemed inoperable, and those with degenerated surgical bioprosthetic valves.

Keywords

Transcatheter aortic valve implantation Indications Low risk Bicuspid aortic valve Aortic regurgitation Failed bioprosthesis 

Notes

Compliance with Ethical Standards

Conflict of Interest

Anna Franzone declares no conflict of interest.

Thomas Pilgrim reports grants from Edwards Lifesciences, Symetis, and Biotronik.

Stefan Stortecky reports grants to the institution from Boston Scientific, Edwards Lifesciences, Medtronic, St. Jude Medical, and Symetis.

Stephan Windecker reports grants to the institution from Boston Scientific, Bracco Pharmaceutical, Terumo Inc., and St. Jude Medical.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106(24):3006–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl J Med. 2012;366(18):1696–704.CrossRefPubMedGoogle Scholar
  3. 3.
    Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, et al. 5-Year outcomes of transcatheter aortic valve replacement compared with standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385(9986):2485–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. N Engl J Med. 2011;364(23):2187–98.CrossRefPubMedGoogle Scholar
  5. 5.
    Adams DH, Popma JJ, Reardon MJ, Yakubov SJ, Coselli JS, Deeb GM, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. N Engl J Med. 2014;370(19):1790–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Reardon MJ, Adams DH, Kleiman NS, Yakubov SJ, Coselli JS, Deeb GM, et al. 2-Year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. J Am Coll Cardiol. 2015;66(2):113–21.CrossRefPubMedGoogle Scholar
  7. 7.
    Deeb GM, Reardon MJ, Chetcuti S, Patel HJ, Grossman PM, Yakubov SJ, et al. 3-Year outcomes in high-risk patients who underwent surgical or transcatheter aortic valve replacement. J Am Coll Cardiol. 2016;67(22):2565–74.CrossRefPubMedGoogle Scholar
  8. 8.
    Joint Task Force on the Management of Valvular Heart Disease of the European Society of C, European Association for Cardio-Thoracic S, Vahanian A, Alfieri O, Andreotti F, Antunes MJ, et al. Guidelines on the management of valvular heart disease (version 2012). Eur Heart J. 2012;33(19):2451–96.CrossRefGoogle Scholar
  9. 9.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2017;135(25):e1159–e95.CrossRefPubMedGoogle Scholar
  10. 10.
    •• Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2016;374(17):1609–20. This is a pivotal randomized trial assessing the performance of TAVR with balloon-expandable valves to SAVR in patients deemed at intermediate surgical risk CrossRefPubMedGoogle Scholar
  11. 11.
    •• Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, et al. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med. 2017;376(14):1321–31. This is a pivotal randomized trial assessing the performance of TAVR with self-expanding valves compared with SAVR in patients deemed at intermediate surgical risk CrossRefPubMedGoogle Scholar
  12. 12.
    Thyregod HG, Steinbruchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical trial. J Am Coll Cardiol. 2015;65(20):2184–94.CrossRefPubMedGoogle Scholar
  13. 13.
    Kodali S, Thourani VH, White J, Malaisrie SC, Lim S, Greason KL, et al. Early clinical and echocardiographic outcomes after SAPIEN 3 transcatheter aortic valve replacement in inoperable, high-risk and intermediate-risk patients with aortic stenosis. Eur Heart J. 2016;37(28):2252–62.CrossRefPubMedGoogle Scholar
  14. 14.
    Herrmann HC, Thourani VH, Kodali SK, Makkar RR, Szeto WY, Anwaruddin S, et al. One-year clinical outcomes with SAPIEN 3 transcatheter aortic valve replacement in high-risk and inoperable patients with severe aortic stenosis. Circulation. 2016;134(2):130–40.CrossRefPubMedGoogle Scholar
  15. 15.
    Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, et al. Transcatheter aortic valve replacement versus surgical valve replacement in intermediate-risk patients: a propensity score analysis. Lancet. 2016;387(10034):2218–25.CrossRefPubMedGoogle Scholar
  16. 16.
    •• Siontis GC, Praz F, Pilgrim T, Mavridis D, Verma S, Salanti G, et al. Transcatheter aortic valve implantation vs. surgical aortic valve replacement for treatment of severe aortic stenosis: a meta-analysis of randomized trials. Eur Heart J. 2016;37(47):3503–12. This is the first meta-analysis of randomized trials comparing TAVR and SAVR that demonstrates a survival benefit throughout 2 years of follow-up among patients randomly assigned to TAVR that is particularly pronounced among patients undergoing TAVR by transfemoral access and among female patients CrossRefPubMedGoogle Scholar
  17. 17.
    Kodali SK, Williams MR, Smith CR, Svensson LG, Webb JG, Makkar RR, et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. N Engl J Med. 2012;366(18):1686–95.CrossRefPubMedGoogle Scholar
  18. 18.
    Webb J, Gerosa G, Lefevre T, Leipsic J, Spence M, Thomas M, et al. Multicenter evaluation of a next-generation balloon-expandable transcatheter aortic valve. J Am Coll Cardiol. 2014;64(21):2235–43.CrossRefPubMedGoogle Scholar
  19. 19.
    Tchétché D. Thirty-day outcomes of a new self-expanding transcatheter heart valve. Presented at EuroPC. 2017.Google Scholar
  20. 20.
    Mylotte D. Global clinical study results today. Presented at EuroPCR. 2017.Google Scholar
  21. 21.
    Meredith IT, Walters DL, Dumonteil N, Worthley SG, Tchetche D, Manoharan G, et al. 1-Year outcomes with the fully repositionable and retrievable lotus transcatheter aortic replacement valve in 120 high-risk surgical patients with severe aortic stenosis: results of the REPRISE II study. JACC Cardiovasc Interv. 2016;9(4):376–84.CrossRefPubMedGoogle Scholar
  22. 22.
    Manoharan G, Linke A, Moellmann H, Redwood S, Frerker C, Kovac J, et al. Multicentre clinical study evaluating a novel resheathable annular functioning self-expanding transcatheter aortic valve system: safety and performance results at 30 days with the Portico system. EuroIntervention. 2016;12(6):768–74.CrossRefPubMedGoogle Scholar
  23. 23.
    Siontis GC, Juni P, Pilgrim T, Stortecky S, Bullesfeld L, Meier B, et al. Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR: a meta-analysis. J Am Coll Cardiol. 2014;64(2):129–40.CrossRefPubMedGoogle Scholar
  24. 24.
    Nazif TM, Dizon JM, Hahn RT, Xu K, Babaliaros V, Douglas PS, et al. Predictors and clinical outcomes of permanent pacemaker implantation after transcatheter aortic valve replacement: the PARTNER (Placement of AoRtic TraNscathetER Valves) trial and registry. JACC Cardiovasc Interv. 2015;8(1 Pt A):60–9.CrossRefPubMedGoogle Scholar
  25. 25.
    • Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al. 5-Year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. Lancet. 2015;385(9986):2477–84. This study reports the longest available follow-up of patients included in a randomized trial comparing TAVR and SAVR with sustained hemodynamic benefit throughout 5 years CrossRefPubMedGoogle Scholar
  26. 26.
    Franzone APT; Haynes A., Lanz J., Asami M., Praz F., Raeber L., Roost E., Langhammer B., Windecker S., Stortecky S. Transcatheter aortic valve thrombosis: incidence, clinical presentation and long-term outcomes. Eur Heart J Cardiovasc Imaging. In press. 2017.Google Scholar
  27. 27.
    Chakravarty T, Sondergaard L, Friedman J, De Backer O, Berman D, Kofoed KF, et al. Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study. Lancet. 2017 Jun 17;389(10087):2383-2392Google Scholar
  28. 28.
    Hansson NC, Grove EL, Andersen HR, Leipsic J, Mathiassen ON, Jensen JM, et al. Transcatheter aortic valve thrombosis: incidence, predisposing factors, and clinical implications. J Am Coll Cardiol. 2016;68(19):2059–69.CrossRefPubMedGoogle Scholar
  29. 29.
    Franzone A, Pilgrim T, Arnold N, Heg D, Langhammer B, Piccolo R, et al. Rates and predictors of hospital readmission after transcatheter aortic valve implantation. Eur Heart J. 2017 Jul 21;38(28):2211-2217Google Scholar
  30. 30.
    Vohra HA, Whistance RN, De Kerchove L, Punjabi P, El Khoury G. Valve-preserving surgery on the bicuspid aortic valve. Eur J Cardiothorac Surg. 2013;43(5):888–98.CrossRefPubMedGoogle Scholar
  31. 31.
    Roberts WC. The congenitally bicuspid aortic valve. A study of 85 autopsy cases. Am J Cardiol. 1970;26(1):72–83.CrossRefPubMedGoogle Scholar
  32. 32.
    Mack MJ, Brennan JM, Brindis R, Carroll J, Edwards F, Grover F, et al. Outcomes following transcatheter aortic valve replacement in the United States. JAMA. 2013;310(19):2069–77.CrossRefPubMedGoogle Scholar
  33. 33.
    Hayashida K, Bouvier E, Lefevre T, Chevalier B, Hovasse T, Romano M, et al. Transcatheter aortic valve implantation for patients with severe bicuspid aortic valve stenosis. Circ Cardiovasc Interv. 2013;6(3):284–91.CrossRefPubMedGoogle Scholar
  34. 34.
    Praz F, Windecker S, Huber C, Carrel T, Wenaweser P. Expanding indications of transcatheter heart valve interventions. JACC Cardiovasc Interv. 2015;8(14):1777–96.CrossRefPubMedGoogle Scholar
  35. 35.
    Mylotte D, Lefevre T, Sondergaard L, Watanabe Y, Modine T, Dvir D, et al. Transcatheter aortic valve replacement in bicuspid aortic valve disease. J Am Coll Cardiol. 2014;64(22):2330–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Perlman GY, Blanke P, Dvir D, Pache G, Modine T, Barbanti M, et al. Bicuspid aortic valve stenosis: favorable early outcomes with a next-generation transcatheter heart valve in a multicenter study. JACC Cardiovasc Interv. 2016;9(8):817–24.CrossRefPubMedGoogle Scholar
  37. 37.
    Yoon SH, Lefevre T, Ahn JM, Perlman GY, Dvir D, Latib A, et al. Transcatheter aortic valve replacement with early- and new-generation devices in bicuspid aortic valve stenosis. J Am Coll Cardiol. 2016;68(11):1195–205.CrossRefPubMedGoogle Scholar
  38. 38.
    Kappetein AP, Head SJ, Genereux P, Piazza N, van Mieghem NM, Blackstone EH, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Am Coll Cardiol. 2012;60(15):1438–54.CrossRefPubMedGoogle Scholar
  39. 39.
    Yoon SH, Bleiziffer S, De Backer O, Delgado V, Arai T, Ziegelmueller J, et al. Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis. J Am Coll Cardiol. 2017;69(21):2579–89.CrossRefPubMedGoogle Scholar
  40. 40.
    Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, Levang OW, et al. A prospective survey of patients with valvular heart disease in Europe: the Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003;24(13):1231–43.CrossRefPubMedGoogle Scholar
  41. 41.
    Roy DA, Schaefer U, Guetta V, Hildick-Smith D, Mollmann H, Dumonteil N, et al. Transcatheter aortic valve implantation for pure severe native aortic valve regurgitation. J Am Coll Cardiol. 2013;61(15):1577–84.CrossRefPubMedGoogle Scholar
  42. 42.
    Schlingloff F, Schafer U, Frerker C, Schmoeckel M, Bader R. Transcatheter aortic valve implantation of a second-generation valve for pure aortic regurgitation: procedural outcome, haemodynamic data and follow-up. Interact Cardiovasc Thorac Surg. 2014;19(3):388–93.CrossRefPubMedGoogle Scholar
  43. 43.
    Seiffert M, Bader R, Kappert U, Rastan A, Krapf S, Bleiziffer S, et al. Initial German experience with transapical implantation of a second-generation transcatheter heart valve for the treatment of aortic regurgitation. JACC Cardiovasc Interv. 2014;7(10):1168–74.CrossRefPubMedGoogle Scholar
  44. 44.
    Franzone A, Piccolo R, Siontis GC, Lanz J, Stortecky S, Praz F, et al. Transcatheter aortic valve replacement for the treatment of pure native aortic valve regurgitation: a systematic review. JACC Cardiovasc Interv. 2016;9(22):2308–17.CrossRefPubMedGoogle Scholar
  45. 45.
    Seiffert M, Diemert P, Koschyk D, Schirmer J, Conradi L, Schnabel R, et al. Transapical implantation of a second-generation transcatheter heart valve in patients with noncalcified aortic regurgitation. JACC Cardiovasc Interv. 2013;6(6):590–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Sawaya FJ, Deutsch MA, Seiffert M, Yoon SH, Codner P, Wickramarachchi U, et al. Safety and efficacy of transcatheter aortic valve replacement in the treatment of pure aortic regurgitation in native valves and failing surgical bioprostheses: results from an international registry study. JACC Cardiovasc Interv. 2017;10(10):1048–56.CrossRefPubMedGoogle Scholar
  47. 47.
    Wenaweser P, Buellesfeld L, Gerckens U, Grube E. Percutaneous aortic valve replacement for severe aortic regurgitation in degenerated bioprosthesis: the first valve in valve procedure using the Corevalve Revalving system. Catheter Cardiovasc Interv. 2007;70(5):760–4.CrossRefPubMedGoogle Scholar
  48. 48.
    Jones JM, O'Kane H, Gladstone DJ, Sarsam MA, Campalani G, MacGowan SW, et al. Repeat heart valve surgery: risk factors for operative mortality. J Thorac Cardiovasc Surg. 2001;122(5):913–8.CrossRefPubMedGoogle Scholar
  49. 49.
    Dvir D, Webb JG, Bleiziffer S, Pasic M, Waksman R, Kodali S, et al. Transcatheter aortic valve implantation in failed bioprosthetic surgical valves. JAMA. 2014;312(2):162–70.CrossRefPubMedGoogle Scholar
  50. 50.
    Deeb GM, Chetcuti SJ, Reardon MJ, Patel HJ, Grossman PM, Schreiber T, et al. 1-Year results in patients undergoing transcatheter aortic valve replacement with failed surgical bioprostheses. JACC Cardiovasc Interv. 2017;10(10):1034–44.CrossRefPubMedGoogle Scholar
  51. 51.
    Dvir D, Webb J, Brecker S, Bleiziffer S, Hildick-Smith D, Colombo A, et al. Transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: results from the global valve-in-valve registry. Circulation. 2012;126(19):2335–44.CrossRefPubMedGoogle Scholar
  52. 52.
    Azadani AN, Tseng EE. Transcatheter heart valves for failing bioprostheses: state-of-the-art review of valve-in-valve implantation. Circ Cardiovasc Interv. 2011;4(6):621–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Paradis JM, Del Trigo M, Puri R, Rodes-Cabau J. Transcatheter valve-in-valve and valve-in-ring for treating aortic and mitral surgical prosthetic dysfunction. J Am Coll Cardiol. 2015;66(18):2019–37.CrossRefPubMedGoogle Scholar
  54. 54.
    Ye J, Cheung A, Yamashita M, Wood D, Peng D, Gao M, et al. Transcatheter aortic and mitral valve-in-valve implantation for failed surgical bioprosthetic valves: an 8-year single-center experience. JACC Cardiovasc Interv. 2015;8(13):1735–44.CrossRefPubMedGoogle Scholar
  55. 55.
    McElhinney DB, Cabalka AK, Aboulhosn JA, Eicken A, Boudjemline Y, Schubert S, et al. Transcatheter tricuspid valve-in-valve implantation for the treatment of dysfunctional surgical bioprosthetic valves: an international, Multicenter Registry Study. Circulation. 2016;133(16):1582–93.CrossRefPubMedGoogle Scholar
  56. 56.
    Ruel M, Kulik A, Rubens FD, Bedard P, Masters RG, Pipe AL, et al. Late incidence and determinants of reoperation in patients with prosthetic heart valves. Eur J Cardiothorac Surg. 2004;25(3):364–70.CrossRefPubMedGoogle Scholar
  57. 57.
    Wijesinghe N, Ye J, Rodés-Cabau J, Cheung A, Velianou JL, Natarajan MK, et al. Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis. JACC Cardiovasc Interv. 2010;3(11):1122–5.CrossRefPubMedGoogle Scholar
  58. 58.
    Himbert D, Pontnau F, Messika-Zeitoun D, Descoutures F, Détaint D, Cueff C, et al. Feasibility and outcomes of transcatheter aortic valve implantation in high-risk patients with stenotic bicuspid aortic valves. Am J Cardiol. 2012;110(6):877–83.CrossRefPubMedGoogle Scholar
  59. 59.
    Kochman J, Huczek Z, Scislo P, Dabrowski M, Chmielak Z, Szymanski P, et al. Comparison of one- and 12-month outcomes of transcatheter aortic valve replacement in patients with severely stenotic bicuspid versus tricuspid aortic valves (results from a multicenter registry). Am J Cardiol. 2014;114(5):757–62.CrossRefPubMedGoogle Scholar
  60. 60.
    Bauer T, Linke A, Sievert H, Kahlert P, Hambrecht R, Nickenig G, et al. Comparison of the effectiveness of transcatheter aortic valve implantation in patients with stenotic bicuspid versus tricuspid aortic valves (from the German TAVI Registry). Am J Cardiol. 2014;113(3):518–21.CrossRefPubMedGoogle Scholar
  61. 61.
    Yousef A, Simard T, Webb J, Rodés-Cabau J, Costopoulos C, Kochman J et al. Transcatheter aortic valve implantation in patients with bicuspid aortic valve: a patient level multi-center analysis. Transcatheter aortic valve implantation in patients with bicuspid aortic valve: a patient level multi-center analysis.Google Scholar
  62. 62.
    Frerker C, Schewel J, Schewel D, Wohlmuth P, Schmidt T, Kreidel F, et al. Expansion of the indication of transcatheter aortic valve implantation--feasibility and outcome in “off-label” patients compared with “on-label” patients. J Invasive Cardiol. 2015;27(5):229–36.PubMedGoogle Scholar
  63. 63.
    Guo Y, Zhu D. Transcatheter aortic valve implantation using a new TAVI system J-valve for high-risk patients with pure aortic regurgitation. J Am Coll Cardiol. 2015;66 Suppl B.Google Scholar
  64. 64.
    Koschyk D, Seiffert M, Conradi L. Transcatheter aortic valve implantation for noncalcified pure aortic insufficiency-initial results and follow-up. Catheter Cardiovasc Interv. 2014; 83(S1).Google Scholar
  65. 65.
    Munoz-Garcia E, Munoz-Garcia M, Munoz-Garcia AJ. Safety of transcatheter aortic valve implantation in patients with pure native aortic valve regurgitation. Eur Heart J. 2015;36. 793 (abstr).Google Scholar
  66. 66.
    Rossi ML, Barbaro C, Pagnotta P, Lucarelli C, Mennuni M, Presbitero P. Transcatheter aortic valve implantation in patients with pure severe native aortic regurgitation: results after 3 year of follow-up (abstr). J Am Coll Cardiol. 2014;64 Suppl B B220-1.Google Scholar
  67. 67.
    Schofer J, Nietlispach F, Bijuklic K, Colombo A, Gatto F, De Marco F, et al. Transfemoral implantation of a fully repositionable and retrievable transcatheter valve for noncalcified pure aortic regurgitation. JACC Cardiovasc Interv. 2015;8(14):1842–9.CrossRefPubMedGoogle Scholar
  68. 68.
    Testa L, Latib A, Rossi ML, De Marco F, De Carlo M, Fiorina C, et al. CoreValve implantation for severe aortic regurgitation: a multicentre registry. EuroIntervention. 2014;10(6):739–45.CrossRefPubMedGoogle Scholar
  69. 69.
    Wei L, Liu H, Zhu L, Yang Y, Zheng J, Guo K, et al. A new transcatheter aortic valve replacement system for predominant aortic regurgitation implantation of the J-valve and early outcome. JACC Cardiovasc Interv. 2015;8(14):1831–41.CrossRefPubMedGoogle Scholar
  70. 70.
    Wendt D, Kahlert P, Pasa S, El-Chilali K, Al-Rashid F, Tsagakis K, et al. Transapical transcatheter aortic valve for severe aortic regurgitation: expanding the limits. JACC Cardiovasc Interv. 2014;7(10):1159–67.CrossRefPubMedGoogle Scholar
  71. 71.
    Zhu D, Chen Y, Guo Y, Hu J, Zhang J, Wei X, et al. Transapical transcatheter aortic valve implantation using a new second-generation TAVI system - J-Valve™ for high-risk patients with aortic valve diseases: Initial results with 90-day follow-up. Int J Cardiol. 2015;199:155–62.CrossRefPubMedGoogle Scholar
  72. 72.
    Sawaya FJ, Deutsch MA, Seiffert M, Yoon SH, Codner P, Wickramarachchi U, et al. Safety and efficacy of transcatheter aortic valve replacement in the treatment of pure aortic regurgitation in native valves and failing surgical bioprostheses: results from an international registry study. JACC Cardiovasc Interv. 2017;10(10):1048–56.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  • Anna Franzone
    • 1
  • Thomas Pilgrim
    • 1
  • Stefan Stortecky
    • 1
  • Stephan Windecker
    • 1
    Email author
  1. 1.Department of CardiologyBern University Hospital, University of BernBernSwitzerland

Personalised recommendations